Cargando…
Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
Dysautonomia is a common non-motor symptom in Parkinson’s disease (PD). Most dysautonomic symptoms appear due to alterations in the peripheral nerves of the autonomic nervous system, including both the sympathetic and parasympathetic nervous systems. The degeneration of sympathetic nerve fibers and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705692/ https://www.ncbi.nlm.nih.gov/pubmed/34948285 http://dx.doi.org/10.3390/ijms222413488 |
_version_ | 1784622009572917248 |
---|---|
author | Cuenca-Bermejo, Lorena Almela, Pilar Navarro-Zaragoza, Javier Fernández Villalba, Emiliano González-Cuello, Ana-María Laorden, María-Luisa Herrero, María-Trinidad |
author_facet | Cuenca-Bermejo, Lorena Almela, Pilar Navarro-Zaragoza, Javier Fernández Villalba, Emiliano González-Cuello, Ana-María Laorden, María-Luisa Herrero, María-Trinidad |
author_sort | Cuenca-Bermejo, Lorena |
collection | PubMed |
description | Dysautonomia is a common non-motor symptom in Parkinson’s disease (PD). Most dysautonomic symptoms appear due to alterations in the peripheral nerves of the autonomic nervous system, including both the sympathetic and parasympathetic nervous systems. The degeneration of sympathetic nerve fibers and neurons leads to cardiovascular dysfunction, which is highly prevalent in PD patients. Cardiac alterations such as orthostatic hypotension, heart rate variability, modifications in cardiogram parameters and baroreflex dysfunction can appear in both the early and late stages of PD, worsening as the disease progresses. In PD patients it is generally found that parasympathetic activity is decreased, while sympathetic activity is increased. This situation gives rise to an imbalance of both tonicities which might, in turn, promote a higher risk of cardiac damage through tachycardia and vasoconstriction. Cardiovascular abnormalities can also appear as a side effect of PD treatment: L-DOPA can decrease blood pressure and aggravate orthostatic hypotension as a result of a negative inotropic effect on the heart. This unwanted side effect limits the therapeutic use of L-DOPA in geriatric patients with PD and can contribute to the number of hospital admissions. Therefore, it is essential to define the cardiac features related to PD for the monitorization of the heart condition in parkinsonian individuals. This information can allow the application of intervention strategies to improve the course of the disease and the proposition of new alternatives for its treatment to eliminate or reverse the motor and non-motor symptoms, especially in geriatric patients. |
format | Online Article Text |
id | pubmed-8705692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87056922021-12-25 Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence Cuenca-Bermejo, Lorena Almela, Pilar Navarro-Zaragoza, Javier Fernández Villalba, Emiliano González-Cuello, Ana-María Laorden, María-Luisa Herrero, María-Trinidad Int J Mol Sci Review Dysautonomia is a common non-motor symptom in Parkinson’s disease (PD). Most dysautonomic symptoms appear due to alterations in the peripheral nerves of the autonomic nervous system, including both the sympathetic and parasympathetic nervous systems. The degeneration of sympathetic nerve fibers and neurons leads to cardiovascular dysfunction, which is highly prevalent in PD patients. Cardiac alterations such as orthostatic hypotension, heart rate variability, modifications in cardiogram parameters and baroreflex dysfunction can appear in both the early and late stages of PD, worsening as the disease progresses. In PD patients it is generally found that parasympathetic activity is decreased, while sympathetic activity is increased. This situation gives rise to an imbalance of both tonicities which might, in turn, promote a higher risk of cardiac damage through tachycardia and vasoconstriction. Cardiovascular abnormalities can also appear as a side effect of PD treatment: L-DOPA can decrease blood pressure and aggravate orthostatic hypotension as a result of a negative inotropic effect on the heart. This unwanted side effect limits the therapeutic use of L-DOPA in geriatric patients with PD and can contribute to the number of hospital admissions. Therefore, it is essential to define the cardiac features related to PD for the monitorization of the heart condition in parkinsonian individuals. This information can allow the application of intervention strategies to improve the course of the disease and the proposition of new alternatives for its treatment to eliminate or reverse the motor and non-motor symptoms, especially in geriatric patients. MDPI 2021-12-16 /pmc/articles/PMC8705692/ /pubmed/34948285 http://dx.doi.org/10.3390/ijms222413488 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cuenca-Bermejo, Lorena Almela, Pilar Navarro-Zaragoza, Javier Fernández Villalba, Emiliano González-Cuello, Ana-María Laorden, María-Luisa Herrero, María-Trinidad Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence |
title | Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence |
title_full | Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence |
title_fullStr | Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence |
title_full_unstemmed | Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence |
title_short | Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence |
title_sort | cardiac changes in parkinson’s disease: lessons from clinical and experimental evidence |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705692/ https://www.ncbi.nlm.nih.gov/pubmed/34948285 http://dx.doi.org/10.3390/ijms222413488 |
work_keys_str_mv | AT cuencabermejolorena cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence AT almelapilar cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence AT navarrozaragozajavier cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence AT fernandezvillalbaemiliano cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence AT gonzalezcuelloanamaria cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence AT laordenmarialuisa cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence AT herreromariatrinidad cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence |